Botanix Pharmaceuticals (ASX: BOT) — Perfil da empresa, notícias e dados financeiros
Botanix Pharmaceuticals is a dermatology company developing topical treatments for serious skin conditions like axillary hyperhidrosis.
Botanix Pharmaceuticals
Botanix Pharmaceuticals is a clinical and commercial stage dermatology company focused on the development and commercialisation of novel topical treatments for common skin diseases and bacterial infections. Headquartered in Australia with operations in the United States, the company's lead commercial product is Sofdra (sofpironium) topical gel, an FDA-approved prescription gel indicated for the treatment of primary axillary hyperhidrosis. Botanix also advances a novel pipeline of topical antimicrobial and anti-inflammatory candidates utilizing drug delivery technologies to treat dermatological conditions such as acne, papulopustular rosacea, and superficial skin infections caused by resistant bacteria.
Resumo
Operações
Produtos e/ou serviços de Botanix Pharmaceuticals
- Primary Hyperhidrosis Treatment: An FDA-approved topical anticholinergic prescription gel formulated with sofpironium bromide at a twelve point forty-five percent concentration for the commercial treatment of primary axillary hyperhidrosis in adult and pediatric patients.
- Acne Vulgaris Pipeline Candidate: A clinical-stage topical formulation candidate developed for the treatment of moderate to severe acne vulgaris through targeted reduction of sebum production, localized inflammation, and follicular hyperkeratinization in patient dermatological trials.
- Antimicrobial Decolonization Candidate: A novel topical antimicrobial drug candidate targeting Staphylococcus aureus infections, developed for nasal decolonization to prevent surgical site complications and manage recurrent superficial bacterial skin infections in clinical settings.
- Papulopustular Rosacea Candidate: A phase two clinical-stage topical formulation designed to target specific inflammatory pathways for the treatment of moderate to severe papulopustular rosacea and associated facial skin erythema and inflammatory lesions.
- Topical Drug Delivery Technology: A proprietary topical delivery formulation platform engineered to enhance skin penetration, improve active drug bioavailability, and enable controlled localized delivery of pharmaceutical compounds through dermal barriers for various dermatological indications.
- Commercial Distribution Infrastructure: United States commercial distribution and medical affairs operations supporting prescription sales, product logistics, specialty pharmacy distribution networks, physician education, and patient access support programs for prescription dermatological therapies.
equipe executiva do Botanix Pharmaceuticals
- Vincent P. IppolitoExecutive Chairman
- Howie McKibbonChief Executive Officer
- Graeme MorisseyChief Financial Officer
- Chris LesovitzChief Financial Officer of United States of America
- Paul SeabackChief Operating Officer
- Boris MeyersonChief Business Officer
- David MorganHead of Corporate Affairs
- Andrew BickleyCompany Secretary
- Darin Van ArsdaleDirector of Sales Operations
Últimas notícias sobre a Botanix Pharmaceuticals
Comunicados recentes
O que a Botanix Pharmaceuticals (BOT) comunicou ao mercado, do mais recente para o mais antigo.
- 2026 Annual General Meeting - Key Dates
Principais indicadores financeiros
Resultados divulgados pela Botanix Pharmaceuticals, em AUD.
- Cap. de mercado
- 33,1 mi
- Receita (TTM)
- 33,8 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.0
- Dividend yield
- —
- Margem de lucro
- -206.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 34,5 mi | -69,3 mi | -69,8 mi | |
| 5,8 mi | -80,8 mi | -86,4 mi | |
| 601,8 mil | -15,7 mi | -13,9 mi | |
| 915 mil | -12,8 mi | -9,2 mi |